Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses ...

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications Shares of Adaptimmune Therapeutics more than tripled in value after the company reported that its SPEAR T-cell platform delivered positive initial responses in...
Streetwise Reports | January 14, 2020 |

Nine responses to the "gold is a bubble" crowd

The “Gold is a Bubble” crowd has been reawakened. CNN warned earlier this week: Gold is a bubble, resist its charms. Gold’s six percent fall in the last six weeks and the Amex Gold Bugs Index (HUI) nearly 20% decline have signaled ...
Andrew Mickey | October 28, 2012 |

Mickey Fulp | We Need to be Paying Attention to This!

The Mercenary Geologist Mickey Fulp the Mercenary Geologist sits down with Maurice Jackson of Proven and Probable to discuss the pernicious erosion of the Bill of Rights as both federal government and municipalities expand their footprint through ...
Maurice Jackson | April 1, 2020 |

How BioVaxys' DPX platform creates anti-cancer immune response

Discover BioVaxys’ innovative DPX™ platform, a cutting-edge lipid-based delivery system transforming immunotherapy. This video explores how the company’s proprietary technology encapsulates diverse bioactive molecules, enhancing and sustai...
Research | October 8, 2024 |

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation

Shares of NantKwest Inc. spiked as much as 85% higher in mid-morning trading setting a new 52-week high price after the company reported a series of positive results at the 38th J.P. Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were ...
Streetwise Reports | January 17, 2020 |

Mersana Therapeutics Trades 60% Higher on Positive Phase 1 Ovarian Cancer Trial Data

Shares of Mersana Therapeutics reached a new 52-week high price after the company reported positive interim data from the expanded portion of its Phase 1 study of XMT-1536 for treatment of ovarian cancer. Clinical-stage biopharmaceutical company Mersana Therapeuti...
Streetwise Reports | May 28, 2020 |

Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity

These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. In a June 22 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Targovax ASA's (TRVX:OSE) ONCOS-102, in trial ...
Streetwise Reports | June 25, 2020 |

BVT's Chairman On Agritech Firm's Massive Growth and Success

Investors are getting excited over a radical new farming technology that is making waves in the media, and in the market. Omri Wallach of Stockhouse Media was recently joined by Michael Collinson, Chairman of the company behind the technology, Bee Vectoring...
Omri Wallach | November 5, 2019 |

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection....
Streetwise Reports | October 4, 2019 |

After Biotech Dives Deeper Into Melanoma Data, It 'Continues to Impress'

Details from this clinical program are discussed, along with Q2/19 earnings and the next stock catalyst, in an H.C. Wainwright & Co. report. In an Aug. 23 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported the highlights from Targovax ASA's (TRVX:...
Streetwise Reports | August 28, 2019 |
1 2 3 4 5 6 7 8 9 10 ...